Cardiovascular & Thoracic Surgery News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These data were both featured today during the American Society of Hematology (ASH) 2021 Annual Meeting. New secondary endpoint data from the Phase 3 GLOW study (NCT03462719) showed that fixed-duration treatment with I+V resulted in undetectable min...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy
This study recruited patients with unresectable pleural mesothelioma who had not received prior chemotherapy. The primary endpoint of median overall survival was significantly longer with the addition of bevacizumab to chemotherapy at 18.8 months versus 16.1 months with chemotherapy alone. However, adverse events such as hypertension and bleeding were more common in the bevacizumab group. More recently, studies such as the phase II RAMSES trial in 2020 have shown promising results for combining anti-VEGF medication with chemotherapy as a second-line treatment. The addition of the VEGF inhibitor ramucirumab significan...
Source: Asbestos and Mesothelioma News - December 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Virtua Health recruits Johns Hopkins surgeon to lead cardiovascular services line
Virtua Health has a new leader for cardiovascular services. The South Jersey health system has hired Dr. Chun "Dan" Choi to serve as Virtua's vice president of clinical operations for its heart care service line. The job was previously held by Dr. Reginald Blaber, who occupied the role in addition to serving as CEO of Lourdes Health System — which Virtu a acquired in 2019. Blaber maintained clinical oversight of cardiovascular services following the acquisition and will continue as executive… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 30, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

Intercostal Nerve Block Cuts Opioids After Thoracic Surgery Intercostal Nerve Block Cuts Opioids After Thoracic Surgery
Intercostal nerve block reduced pain and decreased opioid use in patients who had undergone thoracic surgery, a new meta-analysis shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 24, 2021 Category: Consumer Health News Tags: General Surgery News Source Type: news

Weight Loss Surgery'Best Treatment' for Fatty Liver Disease Weight Loss Surgery'Best Treatment' for Fatty Liver Disease
Bariatric surgery significantly reduces the risk of major adverse liver and cardiovascular events in recipients, compared with nonsurgical counterparts, among those with nonalcoholic fatty liver disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Calgary surgeon saves 2 men with CPR, then performs their heart operations
Dr. Corey Adams, a cardiac surgeon at the University of Calgary's Libin Cardiovascular Institute, has saved two men in the past 18 months by performing CPR on them in public and, days later, operating on them. (Source: CBC | Health)
Source: CBC | Health - November 9, 2021 Category: Consumer Health News Tags: News/Canada/Calgary Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Study Supports Opdivo as Second-Line Mesothelioma Treatment
When the effectiveness of first-line chemotherapy fails and malignant mesothelioma returns, more patients could soon turn with confidence to a proven, second-line treatment. The first phase III, placebo-controlled, double-blind clinical trial studying the safety and efficacy of Opdivo, the immunotherapy drug known generically as nivolumab, has raised the level of confidence in this option for patients with relapsed disease. “The evidence is robust, the survival significant,” Dr. Dean Fennell, chair of Thoracic Medical Oncology, University of Leicester and University Hospitals in the United Kingdom, told The Mesot...
Source: Asbestos and Mesothelioma News - November 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Meadors Moves to CHI St. Vincent (Movers & Shakers)
Dr. Steven Meadors, a vascular surgeon, has joined the CHI St. Vincent Heart Institute and is seeing patients at the CHI St. Vincent Cardiovascular Surgery Clinic in Little Rock. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - October 18, 2021 Category: American Health Source Type: news

Trauma team activation: which surgical capability is immediately required in polytrauma? A retrospective, monocentric analysis of emergency procedures performed on 751 severely injured patients - Schmitt D, Halvachizadeh S, Steinemann R, Jensen KO, Berk T, Neuhaus V, Mica L, Pfeifer R, Pape HC, Sprengel K.
There has been an ongoing discussion as to which interventions should be carried out by an "organ specialist" (for example, a thoracic or visceral surgeon) or by a trauma surgeon with appropriate general surgical training in polytrauma patients. However, t... (Source: SafetyLit)
Source: SafetyLit - October 15, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

EPA Settles Lawsuits, Agrees to Broader Asbestos Risk Evaluations
Facing legal pressure from health and advocacy organizations, the U.S. Environmental Protection Agency has agreed to broaden its ongoing Risk Evaluation for Asbestos under the Toxic Substances Control Act. An agreement to settle two lawsuits – both alleging inadequate evaluation of toxic asbestos – was filed Oct. 13 in the U.S. Court of Appeals for the Ninth Circuit in San Francisco. The Asbestos Disease Awareness Organization was the lead plaintiff in the risk evaluation litigation and was joined by health organizations, scientists and doctors, including acclaimed thoracic surgeon Dr. Raja Flores of Mount Sinai ...
Source: Asbestos and Mesothelioma News - October 14, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Patient Gifts Cakes Every Year to Doctor Who Saved His Life Patient Gifts Cakes Every Year to Doctor Who Saved His Life
For the past 15 years, a Rhode Island man has delivered cakes with messages of appreciation to the cardiovascular surgeon who operated on him, thanking him for another year of life.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 7, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making it t...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news